Oslo University Hospital diversifies its patient offering and scales up the use of Integrum’s OPRA[TM] Implant System

Mölndal, Sweden, September 13^th, 2022 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announced that the Oslo University Hospital (Rikshospitalet) will expand its patient offering to include the OPRA^TM Implant System adapted for artificial thumb replacement surgery. Rikshospitalet has previously performed surgeries using OPRA^TM Implant System in above-knee patients and is now scaling up the number of surgeries in eligible patients.

In April of this year, the Department of Orthopaedics at Rikshospitalet successfully performed its first surgeries using OPRA^TM Implant System in two patients with above-knee amputations. The first patient is now fully treated, and the department will expand its osseointegration program to include the OPRA^TM Implant System for artificial thumb replacement, adding to the current offering that includes artificial trans-femoral and trans-humeral replacement treatments.

“Rikshospitalet and professor Magne Røkkum have been very successful in introducing the use of OPRA^TM in clinical treatment of patients in Norway who require artificial limb replacement. We are also very happy that the department has now decided to expand their use of our technology portfolio to thumb amputations, and we expect Rikshospitalet to treat an increasing volume of eligible patients,” comments Professor Rickard Brånemark, CEO of Integrum.

Integrum’s OPRA^TM Implant System is a bone-anchored system based on osseointegration. As the prostheses are directly attached to the bone, the use of a socket is avoided, leading to fewer complications and better quality of life for the patient.